Equibles does not estimate personal net worth.
Get an email with a short summary when TScan Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get TCRX alertsGavin MacBeath is recorded as CFO at TScan Therapeutics, Inc. (TCRX) since July 21, 2023 and CEO at TScan Therapeutics, Inc. (TCRX) since May 24, 2023. TScan Therapeutics, Inc. reported in an 8-K filed September 2, 2026 that Gavin MacBeath was appointed principal financial officer and principal accounting officer, effective September 2, 2026. TScan Therapeutics, Inc. reported in an 8-K filed May 31, 2023 that Gavin MacBeath was appointed Class I director, effective May 24, 2023. TScan Therapeutics, Inc. reported in an 8-K filed May 31, 2023 that Gavin MacBeath was appointed Chief Executive Officer, effective May 24, 2023. Equibles holds 4 filed executive changes naming Gavin MacBeath; each is listed under recent activity with its source filing. The proxy statement of TScan Therapeutics, Inc. reports total compensation of $2,801,450 for Gavin MacBeath in fiscal 2025, including a base salary of $665,000. Disclosed compensation is on record for 5 fiscal years. Gavin MacBeath has spoken on 2 investor events across 1 company, most recently for TScan Therapeutics, Inc. on June 30, 2026. TScan Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at TScan Therapeutics, Inc. includes Stephen Biggar (Chairman), Brian Silver (CFO), Jason A. Amello (Chief Accounting Officer and Board Member) and 7 others.
“As of the Effective Date, Gavin MacBeath, Ph.D., the Company's Chief Executive Officer, assumed the duties of the principal financial officer and principal accounting officer of the Company.”
“On May 24, 2023, the Board of Directors (the "Board") of TScan Therapeutics, Inc. (the "Company") appointed Gavin MacBeath, Ph.D., as Chief Executive Officer and member the Board, effective May 24, 2023.”
“So, yeah, so T-Scan is a clinical stage, fully integrated TCR T-cell therapy company. We're actually founded back in 2018 and over the years have built a pipeline of various TCR-engineered T-cell therapies for cancer.”
“So T-scan Therapeutics is a fully integrated clinical stage T-cell therapy company focused on bringing TCR-engineered T-cell therapies to patients with cancer.”
2023-07-21–present
2023-05-24–present
SEC 8-K
2022-06-01–present
2018-01-01–2025-05-14
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CFO, CEO
2018-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | TScan Therapeutics, Inc. (TCRX) | Chief Executive Officer and Director | $665,000 | $2,801,450 |
| 2024 | TScan Therapeutics, Inc. (TCRX) | Chief Executive Officer and Director | $620,000 | $1,760,671 |
| 2023 | TScan Therapeutics, Inc. (TCRX) | Chief Executive Officer and Director | $545,121 | $3,196,054 |
| 2022 | TScan Therapeutics, Inc. (TCRX) | Chief Executive Officer and Director | $450,000 | $1,361,727 |
| 2021 | TScan Therapeutics, Inc. (TCRX) | Acting Chief Executive Officer, Chief Scientific and Operating Officer | $400,000 | $1,189,840 |
